Scientific topics
Keywords
ITMO
Anne Galy Expert in cell and gene therapy
Course and current status
Anne Galy was trained in pharmacy, immunology and hematology and has more than 20 years of experience in cell and gene therapy. At Genethon she has developed a gene therapy program to treat primary immune disorders in collaboration with leading international clinical centers. She also established the academic research unit of Genethon (UMR_S951 Integrare affiliated with Université Paris-Saclay, university of Evry and Inserm) which she currently co-directs and comprises about 90 scientific collaborators entirely dedicated to gene therapy research for rare diseases (www.genethon.fr). With Inserm, Dr. Galy has expanded her activities towards more frequent cell and gene therapy indications and has recently established the “technological research accelerator in genomic therapy” (ART-TG) to promote technological innovation and to accelerate industrial or clinical transfer. ART-TG supports in particular, innovative gene-based immunotherapies for cancer and infectious diseases (www.art-tg.com).
Scientific summary
Dr. Galy's research interests concern the gene-modification of immune and blood cells for therapeutic applications.
At Genethon, Dr. Galy has developed a multi-disciplinary and international gene therapy program for hematopoietic stem cell-based gene therapy. Her laboratory has developed lentiviral gene transfer vectors and preclinical studies for the treatment of several primary immune and blood genetic diseases enabling the conduct of phase I/II studies. Positive initial outcomes were observed in patients with Wiskott Aldrich Syndrome, X-linked CGD or Fanconi anemia A and long-term follow up safety and efficacy studies are ongoing. A new project aims to improve the gene therapy of sickle cell disease.
Dr. Galy is also interested in the challenges of in vivo gene delivery, as immune cells are particularly efficient at responding against viral components of vectors and DNA modifications. Dr. Galy has developed endogenized vectors which are leading to new strategies for B cell genetic engineering for novel immunotherapies.
